Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer

Paul A. Bunn, Daniel C. Chan, Keith Earle, Tom L M Zhao, Barbara Helfrich, Karen Kelly, Gary Piazza, Clark M. Whitehead, Rifat Pamukcu, William Thompson, Hector Alila

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Lung cancer is the leading cause of cancer death in the United States. The majority of patients with non-small cell lung cancers present with inoperable disease because of the presence of metastases to regional lymph nodes or other metastatic sites. About one third of patients have stage IV disease with metastases to distant organs at the time of diagnosis. The prognosis for these patients is very poor. With best supportive care the median survival is only 4 months and the 1-year survival rate is 10% to 15%. Current chemotherapy combinations improve the survival and quality of life for patients with advanced non-small cell lung cancer. With two-drug combinations, median survival is increased to 8 months or more and 1-year survival is increased to 35% to 40%. Still, complete response rates are low and more than 80% of patients die within 1 year of diagnosis. The improvements created by current therapies led to studies of chemotherapy in the second-line setting. Docetaxel has been shown to improve survival of patients who failed platinum-based chemotherapy and was approved by the U.S. Food and Drug Administration for therapy in this setting. However, response rates were very low and survival very short. Therefore, new therapies are urgently needed. Exisulind is a novel oral anticancer agent that holds promise for the treatment of patients with advanced non-small cell lung cancer. Exisulind was originally developed as a chemoprevention agent for colorectal cancer. Preclinical studies showed that exisulind could prevent polyp formation and inhibit the growth of colorectal cancers. Subsequent preclinical studies showed that exisulind also inhibited the growth of human breast, prostate, and lung cancers. Phase I clinical studies showed that twice-daily oral doses could be given safely and would provide peak concentrations that were equivalent to those required for in vitro effects. These observations lead to the studies of the combination of exisulind and docetaxel in preclinical and clinical studies in human lung cancer described in this article.

Original languageEnglish (US)
Pages (from-to)87-94
Number of pages8
JournalSeminars in Oncology
Volume29
Issue number1 SUPPL. 4
StatePublished - 2002
Externally publishedYes

Fingerprint

docetaxel
Lung Neoplasms
Survival
Non-Small Cell Lung Carcinoma
Drug Therapy
Therapeutics
Colorectal Neoplasms
Neoplasm Metastasis
Chemoprevention
Drug Combinations
Growth
Polyps
sulindac sulfone
Clinical Studies
Combination Drug Therapy
Platinum
Antineoplastic Agents
Cause of Death
Prostatic Neoplasms
Survival Rate

ASJC Scopus subject areas

  • Oncology

Cite this

Bunn, P. A., Chan, D. C., Earle, K., Zhao, T. L. M., Helfrich, B., Kelly, K., ... Alila, H. (2002). Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer. Seminars in Oncology, 29(1 SUPPL. 4), 87-94.

Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer. / Bunn, Paul A.; Chan, Daniel C.; Earle, Keith; Zhao, Tom L M; Helfrich, Barbara; Kelly, Karen; Piazza, Gary; Whitehead, Clark M.; Pamukcu, Rifat; Thompson, William; Alila, Hector.

In: Seminars in Oncology, Vol. 29, No. 1 SUPPL. 4, 2002, p. 87-94.

Research output: Contribution to journalArticle

Bunn, PA, Chan, DC, Earle, K, Zhao, TLM, Helfrich, B, Kelly, K, Piazza, G, Whitehead, CM, Pamukcu, R, Thompson, W & Alila, H 2002, 'Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer', Seminars in Oncology, vol. 29, no. 1 SUPPL. 4, pp. 87-94.
Bunn PA, Chan DC, Earle K, Zhao TLM, Helfrich B, Kelly K et al. Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer. Seminars in Oncology. 2002;29(1 SUPPL. 4):87-94.
Bunn, Paul A. ; Chan, Daniel C. ; Earle, Keith ; Zhao, Tom L M ; Helfrich, Barbara ; Kelly, Karen ; Piazza, Gary ; Whitehead, Clark M. ; Pamukcu, Rifat ; Thompson, William ; Alila, Hector. / Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer. In: Seminars in Oncology. 2002 ; Vol. 29, No. 1 SUPPL. 4. pp. 87-94.
@article{44edf3ff623a4ec3b3963c97f4bfc859,
title = "Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer",
abstract = "Lung cancer is the leading cause of cancer death in the United States. The majority of patients with non-small cell lung cancers present with inoperable disease because of the presence of metastases to regional lymph nodes or other metastatic sites. About one third of patients have stage IV disease with metastases to distant organs at the time of diagnosis. The prognosis for these patients is very poor. With best supportive care the median survival is only 4 months and the 1-year survival rate is 10{\%} to 15{\%}. Current chemotherapy combinations improve the survival and quality of life for patients with advanced non-small cell lung cancer. With two-drug combinations, median survival is increased to 8 months or more and 1-year survival is increased to 35{\%} to 40{\%}. Still, complete response rates are low and more than 80{\%} of patients die within 1 year of diagnosis. The improvements created by current therapies led to studies of chemotherapy in the second-line setting. Docetaxel has been shown to improve survival of patients who failed platinum-based chemotherapy and was approved by the U.S. Food and Drug Administration for therapy in this setting. However, response rates were very low and survival very short. Therefore, new therapies are urgently needed. Exisulind is a novel oral anticancer agent that holds promise for the treatment of patients with advanced non-small cell lung cancer. Exisulind was originally developed as a chemoprevention agent for colorectal cancer. Preclinical studies showed that exisulind could prevent polyp formation and inhibit the growth of colorectal cancers. Subsequent preclinical studies showed that exisulind also inhibited the growth of human breast, prostate, and lung cancers. Phase I clinical studies showed that twice-daily oral doses could be given safely and would provide peak concentrations that were equivalent to those required for in vitro effects. These observations lead to the studies of the combination of exisulind and docetaxel in preclinical and clinical studies in human lung cancer described in this article.",
author = "Bunn, {Paul A.} and Chan, {Daniel C.} and Keith Earle and Zhao, {Tom L M} and Barbara Helfrich and Karen Kelly and Gary Piazza and Whitehead, {Clark M.} and Rifat Pamukcu and William Thompson and Hector Alila",
year = "2002",
language = "English (US)",
volume = "29",
pages = "87--94",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1 SUPPL. 4",

}

TY - JOUR

T1 - Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer

AU - Bunn, Paul A.

AU - Chan, Daniel C.

AU - Earle, Keith

AU - Zhao, Tom L M

AU - Helfrich, Barbara

AU - Kelly, Karen

AU - Piazza, Gary

AU - Whitehead, Clark M.

AU - Pamukcu, Rifat

AU - Thompson, William

AU - Alila, Hector

PY - 2002

Y1 - 2002

N2 - Lung cancer is the leading cause of cancer death in the United States. The majority of patients with non-small cell lung cancers present with inoperable disease because of the presence of metastases to regional lymph nodes or other metastatic sites. About one third of patients have stage IV disease with metastases to distant organs at the time of diagnosis. The prognosis for these patients is very poor. With best supportive care the median survival is only 4 months and the 1-year survival rate is 10% to 15%. Current chemotherapy combinations improve the survival and quality of life for patients with advanced non-small cell lung cancer. With two-drug combinations, median survival is increased to 8 months or more and 1-year survival is increased to 35% to 40%. Still, complete response rates are low and more than 80% of patients die within 1 year of diagnosis. The improvements created by current therapies led to studies of chemotherapy in the second-line setting. Docetaxel has been shown to improve survival of patients who failed platinum-based chemotherapy and was approved by the U.S. Food and Drug Administration for therapy in this setting. However, response rates were very low and survival very short. Therefore, new therapies are urgently needed. Exisulind is a novel oral anticancer agent that holds promise for the treatment of patients with advanced non-small cell lung cancer. Exisulind was originally developed as a chemoprevention agent for colorectal cancer. Preclinical studies showed that exisulind could prevent polyp formation and inhibit the growth of colorectal cancers. Subsequent preclinical studies showed that exisulind also inhibited the growth of human breast, prostate, and lung cancers. Phase I clinical studies showed that twice-daily oral doses could be given safely and would provide peak concentrations that were equivalent to those required for in vitro effects. These observations lead to the studies of the combination of exisulind and docetaxel in preclinical and clinical studies in human lung cancer described in this article.

AB - Lung cancer is the leading cause of cancer death in the United States. The majority of patients with non-small cell lung cancers present with inoperable disease because of the presence of metastases to regional lymph nodes or other metastatic sites. About one third of patients have stage IV disease with metastases to distant organs at the time of diagnosis. The prognosis for these patients is very poor. With best supportive care the median survival is only 4 months and the 1-year survival rate is 10% to 15%. Current chemotherapy combinations improve the survival and quality of life for patients with advanced non-small cell lung cancer. With two-drug combinations, median survival is increased to 8 months or more and 1-year survival is increased to 35% to 40%. Still, complete response rates are low and more than 80% of patients die within 1 year of diagnosis. The improvements created by current therapies led to studies of chemotherapy in the second-line setting. Docetaxel has been shown to improve survival of patients who failed platinum-based chemotherapy and was approved by the U.S. Food and Drug Administration for therapy in this setting. However, response rates were very low and survival very short. Therefore, new therapies are urgently needed. Exisulind is a novel oral anticancer agent that holds promise for the treatment of patients with advanced non-small cell lung cancer. Exisulind was originally developed as a chemoprevention agent for colorectal cancer. Preclinical studies showed that exisulind could prevent polyp formation and inhibit the growth of colorectal cancers. Subsequent preclinical studies showed that exisulind also inhibited the growth of human breast, prostate, and lung cancers. Phase I clinical studies showed that twice-daily oral doses could be given safely and would provide peak concentrations that were equivalent to those required for in vitro effects. These observations lead to the studies of the combination of exisulind and docetaxel in preclinical and clinical studies in human lung cancer described in this article.

UR - http://www.scopus.com/inward/record.url?scp=0036118264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036118264&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 87

EP - 94

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1 SUPPL. 4

ER -